Zedira’s general approach in medicine targets dysregulated transglutaminase activity in disease states.

In the human body, eight transglutaminases fulfill a broad variety of physiological functions. On the other hand, transglutaminases are involved in the pathophysiology of various disorders. Celiac disease, thrombosis, fibrosis or even cancer and such neurodegenerative diseases as Alzheimer’s, Huntington’s and Parkinson’s disease are just some examples.


Celiac Disease
Zedira’s drug candidate ZED1227 targeting dysregulated TG2 in celiac disease is currently tested in phase 2 clinical trials (proof-of-concept).
read more

Partnering in Drug Development
Zedira offers its proprietary drug discovery platform for partnering in drug development
read more

Gluten Sensitive Neurological Disorders
Auto-antibodies specific for neuronal transglutaminase (TG6) can be measured with our proprietary ELISA-kits.

New: Analytical service for measurement of TG6-autoantibodies in human serum samples..
read more

Thrombosis / Anticoagulation
Proof-of-principle for safe anticoagulation, meaning anticoagulation without increased bleeding risk using blood coagulation factor FXIIIa-blockers has recently been shown.
read more

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
    Read more All news
  • imagePreview: Catalogue Editorial 2019
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
    Read more All news
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
    Read more All news
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
    Read more All news
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    Read more All news
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
    Read more All news
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
    Read more All news
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
    Read more All news
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
    Read more All news
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
    Read more All news
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
    Read more All news
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
    Read more All news

Blog  

Events  

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

    All events
  • 27th ISTH Congress

    06.06.2019 - 10.06.2019
    Melbourne, Australia

    All events
  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

    All events
  • Workshop on Transglutaminase Research

    28.09.2019 - 01.10.2019
    Marrakech, Morocco

    All events